Related Experiment Videos
Pathogenesis of immune-mediated neuropathies
1Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104.
Pediatric Research
|January 1, 1993
Summary
Guillain-Barré syndrome (GBS) is an immune-mediated neuropathy causing progressive weakness. Early plasmapheresis and high-dose immune globulin therapy can shorten paralysis duration in GBS patients.
Area of Science:
- Neuroimmunology
- Neurology
- Pathology
Background:
- Peripheral neuropathies are often immune-mediated, with Guillain-Barré syndrome (GBS) as a primary example.
- GBS presents as acute motor weakness, reduced reflexes, and potential respiratory/autonomic dysfunction.
- Cerebrospinal fluid analysis reveals elevated protein and minimal cells, alongside slowed nerve conduction and segmental demyelination.
Purpose of the Study:
- To explore the immunologic basis of peripheral nerve demyelination in GBS.
- To understand the mechanisms underlying GBS pathogenesis.
- To identify potential autoantigens involved in GBS.
Main Methods:
- Review of human and animal studies on GBS and experimental allergic neuritis (EAN).
- Analysis of cerebrospinal fluid and nerve conduction studies in GBS patients.
- Investigation of animal models (EAN) induced by myelin P2 protein and galactocerebroside.
Main Results:
- EAN models mimic GBS electrophysiologically and pathologically, transferable via P2-reactive T cells or anti-galactocerebroside antibodies.
- GBS patients exhibit antibodies to peripheral nerve myelin and immune complexes.
- Potential targets include glycolipids cross-reactive with Forssman antigen and gangliosides.
Conclusions:
- Evidence strongly suggests an immunologic etiology for GBS-related demyelination.
- Therapeutic strategies include supportive care, plasmapheresis, and high-dose immune globulin therapy.
- Further research is needed to fully elucidate the specific autoantigens in GBS.